Chotsiri P.White N.J.Tarning J.Mahidol University2023-06-182023-06-182022-08-01Trends in Parasitology Vol.38 No.8 (2022) , 673-68214714922https://repository.li.mahidol.ac.th/handle/123456789/84946African children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months and 5 years living in the Sahel region, a region of intense but seasonal malaria transmission. This intervention is now being considered for other regions of Africa where malaria parasites are more drug resistant. Dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), has proved to be highly effective and well tolerated in intermittent preventive treatment in pregnant women and children. This combination may be a suitable alternative for SMC. Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing.Immunology and MicrobiologyReviewSCOPUS10.1016/j.pt.2022.05.0032-s2.0-851318091921471500735688778